| Autor: |
Uhlin M; Department of Microbiology, Tumor and Cell Biology Center and, Karolinska Institutet, Stockholm, Sweden. michael.uhlin@mtc.ki.se, Masucci M, Levitsky V |
| Jazyk: |
angličtina |
| Zdroj: |
Scandinavian journal of immunology [Scand J Immunol] 2006 Dec; Vol. 64 (6), pp. 581-7. |
| DOI: |
10.1111/j.1365-3083.2006.01850.x |
| Abstrakt: |
CD8(+) cytotoxic T lymphocytes (CTL) are important for the immunological control of infections and tumours. Engagement of the T-cell receptor (TCR) with major histocompatibility complex (MHC) class I/peptide complexes on antigen-presenting cells (APC) is the key interaction, which initiates the process of T-cell activation. Depending on the affinity of this interaction, different arrays of signalling pathways and functional outcomes can be activated in the specific T cells. Molecular alterations in the peptide bound to the MHC class I can lead to a lower affinity of the MHC:TCR interaction resulting in incomplete or qualitatively different T-cell responses. Altered peptide ligands (APL) exhibiting such activity are referred to as partial agonists and often occur naturally through genetic instability, which affects T-cell epitopes derived from rapidly mutating viruses or tumour-associated cellular antigens. Partial agonists are usually viewed as peptide variants, which escape efficient CTL recognition. Our recent data suggest that APL can not only trigger incomplete activation but also induce and modulate intrinsic T-cell programmes leading to the shut-off of specific CTL responses. This APL-induced suppression appears to be more prominent in the absence of immunological help, suggesting that under conditions of immune deregulation APL may actively inhibit CTL responses against infectious agents or tumours. In this review, we discuss experimental data supporting this model and possible role of APL-induced immunosuppression in different pathological conditions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
